Response to Letter by Dame

Hannelore Ehrenreich, Claudia Bartels, Karin Weissenborn, Hans-Christoph Diener
2010 Stroke  
Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. They should not exceed 750 words (including references) and may be subject to editing or abridgment. Please submit letters in duplicate, typed double-spaced. Include a fax number for the corresponding author and a completed copyright transfer agreement form (available online at http://stroke.ahajournals.org and http://submit-stroke.ahajournals.org). EPO n=89 EPO n=80 EPO n=68 EPO n=16 40 40 40 40
more » ... 40 40 40 40 baseline day 90 day 30 baseline day 90 day 30 baseline day 90 day 30 baseline day 90 day 30 Placebo n=101 Placebo n=84 Placebo n=62 Placebo n=19 A B C D Figure. A safety risk of recombinant human erythropoietin in ischemic stroke is restricted to patients receiving thrombolysis despite contraindications. ITT indicates intent-to-treat population. (Stroke. 2010;41:e167-e168.)
doi:10.1161/strokeaha.109.575951 fatcat:ei6wm6ocnfg4dmfwhswddzkqqy